James V. Gardiner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
James V. Gardiner has a total of 277 co-authors. Here are the top co-authors by number of shared publications:
- Stephen Robert Bloom
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
23 shared publications - Kevin Graeme Murphy
Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK
21 shared publications - Waljit Singh Dhillo
Section of Endocrinology and Investigative Medicine, Imperial College London , London W12 0NN
20 shared publications - Gavin A. Bewick
Department of Diabetes, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, Guy's Campus, London SE1 1UL, UK. Diabetes, Endocrinology and Obesity clinical academic partnership, Kings Health Partners, London
14 shared publications M. A. Ghatei
Section of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, London W12 ONN, UK
10 shared publicationsMohammad A. Ghatei
Department of Investigative Medicine, Imperial College London, London, U.K.
9 shared publications
Latest Publications
- Open Access
- 1 June 2020
- Published by Elsevier in Molecular Metabolism
- Vol. 36, 100972
Effects of corticosterone within the hypothalamic arcuate nucleus on food intake and body weight in male rats
- 1 June 2020
- Published by Elsevier in Molecular Metabolism
- Vol. 36, 100972
Open AccessEffects of corticosterone within the hypothalamic arcuate nucleus on food intake and body weight in male rats
- Open Access
- 31 March 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (8)
Glucose in the hypothalamic paraventricular nucleus regulates GLP-1 release
Glucokinase (GK) is highly expressed in the hypothalamic paraventricular nucleus (PVN); however, its role is currently unknown. We found that GK in the PVN acts as part of a glucose-sensing mechanism within the PVN that regulates glucose homeostasis by controlling glucagon-like peptide 1 (GLP-1) release. GLP-1 is released from enteroendocrine L cells in response to oral glucose. Here we identify a brain mechanism critical to the release of GLP-1 in response to oral glucose. We show that increasing expression of GK or injection of glucose into the PVN increases GLP-1 release in response to oral glucose. On the contrary, decreasing expression of GK or injection of nonmetabolizable glucose into the PVN prevents GLP-1 release. Our results demonstrate that gluco-sensitive GK neurons in the PVN are critical to the response to oral glucose and subsequent release of GLP-1.
- 31 March 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (8)
Open AccessGlucose in the hypothalamic paraventricular nucleus regulates GLP-1 release
Glucokinase (GK) is highly expressed in the hypothalamic paraventricular nucleus (PVN); however, its role is currently unknown. We found that GK in the PVN acts as part of a glucose-sensing mechanism within the PVN that regulates glucose homeostasis by controlling glucagon-like peptide 1 (GLP-1) release. GLP-1 is released from enteroendocrine L cells in response to oral glucose. Here we identify a brain mechanism critical to the release of GLP-1 in response to oral glucose. We show that increasing expression of GK or injection of glucose into the PVN increases GLP-1 release in response to oral glucose. On the contrary, decreasing expression of GK or injection of nonmetabolizable glucose into the PVN prevents GLP-1 release. Our results demonstrate that gluco-sensitive GK neurons in the PVN are critical to the response to oral glucose and subsequent release of GLP-1.
- 2 November 2018
- Published by Bioscientifica in Endocrine Abstracts
Hypothalamic arcuate glucokinase and its downstream pathways are critical in glucose homeostasis
As the nation gets fatter, the incidence of diabetes is also rising. The brain is now emerging as a critical mediator of blood sugar control, re-directing focus away from the traditional pancreas-centred model. The enzyme glucokinase (GK) acts as a glucose sensor in many tissues including glucose-sensitive neurones within the hypothalamic arcuate nucleus. However, the role of GK here is unclear. We investigated the role of arcuate GK in glucose homeostasis in both healthy and overweight models. We used a recombinant adeno-associated vector (rAAV) expressing either GK (iARC-GK) or antisense GK (iARC-ASGK) to increase or decrease GK activity specifically in the arcuate nucleus of rats. We investigated the subsequent effects on glucose homeostasis. Increased glucokinase activity significantly improved glucose tolerance (7.43±0.23 mmol/L iARC-GFP vs 6.4±0.27 mmol/L iARC-GK, PPPP<0.05). The effect of glucokinase upregulation was maintained in a rodent model of Type 2 diabetes. Interestingly, these obese models were also more sensitive to centrally administered sulphonylureas compared with healthy controls. However, the same sulphonylureas were ineffective when administered peripherally. These results demonstrate a role for arcuate nucleus GK in systemic glucose homeostasis. Increasing glucokinase activity improved blood glucose levels and increased insulin secretion in both healthy and metabolically dysregulated models thereby making it an attractive potential therapeutic target. Furthermore, centrally acting sulphonylureas appear to be more effective in correcting hyperglycaemia than peripherally administered sulphonylureas. This effect is particularly marked in obese models. Hence development of centrally active ligand-directed glucokinase activators or central sulphonylureas working via the glucokinase activation pathway, may herald a new era in anti-diabetic therapy.
- 2 November 2018
- Published by Bioscientifica in Endocrine Abstracts
Hypothalamic arcuate glucokinase and its downstream pathways are critical in glucose homeostasis
As the nation gets fatter, the incidence of diabetes is also rising. The brain is now emerging as a critical mediator of blood sugar control, re-directing focus away from the traditional pancreas-centred model. The enzyme glucokinase (GK) acts as a glucose sensor in many tissues including glucose-sensitive neurones within the hypothalamic arcuate nucleus. However, the role of GK here is unclear. We investigated the role of arcuate GK in glucose homeostasis in both healthy and overweight models. We used a recombinant adeno-associated vector (rAAV) expressing either GK (iARC-GK) or antisense GK (iARC-ASGK) to increase or decrease GK activity specifically in the arcuate nucleus of rats. We investigated the subsequent effects on glucose homeostasis. Increased glucokinase activity significantly improved glucose tolerance (7.43±0.23 mmol/L iARC-GFP vs 6.4±0.27 mmol/L iARC-GK, PPPP<0.05). The effect of glucokinase upregulation was maintained in a rodent model of Type 2 diabetes. Interestingly, these obese models were also more sensitive to centrally administered sulphonylureas compared with healthy controls. However, the same sulphonylureas were ineffective when administered peripherally. These results demonstrate a role for arcuate nucleus GK in systemic glucose homeostasis. Increasing glucokinase activity improved blood glucose levels and increased insulin secretion in both healthy and metabolically dysregulated models thereby making it an attractive potential therapeutic target. Furthermore, centrally acting sulphonylureas appear to be more effective in correcting hyperglycaemia than peripherally administered sulphonylureas. This effect is particularly marked in obese models. Hence development of centrally active ligand-directed glucokinase activators or central sulphonylureas working via the glucokinase activation pathway, may herald a new era in anti-diabetic therapy.
- Open Access
- 11 May 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (9) , 2246-2254
Hypothalamic arcuate nucleus glucokinase regulates insulin secretion and glucose homeostasis
Aims: To investigate the role of arcuate glucokinase (GK) in the regulation of glucose homeostasis. Materials and methods: A recombinant adeno‐associated virus expressing either GK or an antisense GK construct was used to alter GK activity specifically in the hypothalamic arcuate nucleus (arc). GK activity in this nucleus was also increased by stereotactic injection of the GK activator, compound A. The effect of altered arc GK activity on glucose homeostasis was subsequently investigated using glucose and insulin tolerance tests. Results.: Increased GK activity specifically within the arc increased insulin secretion and improved glucose tolerance in rats during oral glucose tolerance tests. Decreased GK activity in this nucleus reduced insulin secretion and increased glucose levels during the same tests. Insulin sensitivity was not affected in either case. The effect of arc GK was maintained in a model of type 2 diabetes. Conclusions: These results demonstrate a role for arc GK in systemic glucose homeostasis.
- 11 May 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (9) , 2246-2254
Open AccessHypothalamic arcuate nucleus glucokinase regulates insulin secretion and glucose homeostasis
Aims: To investigate the role of arcuate glucokinase (GK) in the regulation of glucose homeostasis. Materials and methods: A recombinant adeno‐associated virus expressing either GK or an antisense GK construct was used to alter GK activity specifically in the hypothalamic arcuate nucleus (arc). GK activity in this nucleus was also increased by stereotactic injection of the GK activator, compound A. The effect of altered arc GK activity on glucose homeostasis was subsequently investigated using glucose and insulin tolerance tests. Results.: Increased GK activity specifically within the arc increased insulin secretion and improved glucose tolerance in rats during oral glucose tolerance tests. Decreased GK activity in this nucleus reduced insulin secretion and increased glucose levels during the same tests. Insulin sensitivity was not affected in either case. The effect of arc GK was maintained in a model of type 2 diabetes. Conclusions: These results demonstrate a role for arc GK in systemic glucose homeostasis.
- Open Access
- 30 November 2017
- Published by IOP Publishing in Journal of Neural Engineering
- Vol. 15 (1) , 016001
Extracellular pH monitoring for use in closed-loop vagus nerve stimulation
Vagal nerve stimulation (VNS) has shown potential benefits for obesity treatment; however, current devices lack physiological feedback, which limit their efficacy. Changes in extracellular pH (pHe) have shown to be correlated with neural activity, but have traditionally been measured with glass microelectrodes, which limit their in vivo applicability. Iridium oxide has previously been shown to be sensitive to fluctuations in pH and is biocompatible. Iridium oxide microelectrodes were inserted into the subdiaphragmatic vagus nerve of anaesthetised rats. Introduction of the gut hormone cholecystokinin (CCK) or distension of the stomach was used to elicit vagal nerve activity. Iridium oxide microelectrodes have sufficient pH sensitivity to readily detect changes in pHe associated with both CCK and gastric distension. Furthermore, a custom-made Matlab script was able to use these changes in pHe to automatically trigger an implanted VNS device. This is the first study to show pHe changes in peripheral nerves in vivo. In addition, the demonstration that iridium oxide microelectrodes are sufficiently pH sensitive as to measure changes in pHe associated with physiological stimuli means they have the potential to be integrated into closed-loop neurostimulating devices.
- 30 November 2017
- Published by IOP Publishing in Journal of Neural Engineering
- Vol. 15 (1) , 016001
Open AccessExtracellular pH monitoring for use in closed-loop vagus nerve stimulation
Vagal nerve stimulation (VNS) has shown potential benefits for obesity treatment; however, current devices lack physiological feedback, which limit their efficacy. Changes in extracellular pH (pHe) have shown to be correlated with neural activity, but have traditionally been measured with glass microelectrodes, which limit their in vivo applicability. Iridium oxide has previously been shown to be sensitive to fluctuations in pH and is biocompatible. Iridium oxide microelectrodes were inserted into the subdiaphragmatic vagus nerve of anaesthetised rats. Introduction of the gut hormone cholecystokinin (CCK) or distension of the stomach was used to elicit vagal nerve activity. Iridium oxide microelectrodes have sufficient pH sensitivity to readily detect changes in pHe associated with both CCK and gastric distension. Furthermore, a custom-made Matlab script was able to use these changes in pHe to automatically trigger an implanted VNS device. This is the first study to show pHe changes in peripheral nerves in vivo. In addition, the demonstration that iridium oxide microelectrodes are sufficiently pH sensitive as to measure changes in pHe associated with physiological stimuli means they have the potential to be integrated into closed-loop neurostimulating devices.
- Open Access
- 1 July 2017
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 20 (4) , 261-265
Carbohydrate craving
Purpose of review Cravings for carbohydrates have been known about for hundreds of years but the mechanisms behind it were unclear. This review will highlight recent advances in our knowledge of mechanisms to detect carbohydrates in the diet. Recent findings Recent work has begun to identify the physiological mechanisms by which carbohydrates and glucose are detected and how this drives their intake. Recently, evidence has been found for systems that regulate carbohydrate and glucose intake via taste, hedonic, and homeostatic pathways. Summary Identification of the physiological mechanisms that regulate carbohydrate intake will allow a better understanding of how their intake is regulated and responds to changes in dietary intake. Such an understanding will be a key for developing a more rational approach to the development of successful weight loss diets.
- 1 July 2017
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 20 (4) , 261-265
Open AccessCarbohydrate craving
Purpose of review Cravings for carbohydrates have been known about for hundreds of years but the mechanisms behind it were unclear. This review will highlight recent advances in our knowledge of mechanisms to detect carbohydrates in the diet. Recent findings Recent work has begun to identify the physiological mechanisms by which carbohydrates and glucose are detected and how this drives their intake. Recently, evidence has been found for systems that regulate carbohydrate and glucose intake via taste, hedonic, and homeostatic pathways. Summary Identification of the physiological mechanisms that regulate carbohydrate intake will allow a better understanding of how their intake is regulated and responds to changes in dietary intake. Such an understanding will be a key for developing a more rational approach to the development of successful weight loss diets.
- Open Access
- 6 June 2017
- Published by The Endocrine Society in Endocrinology
- Vol. 158 (8) , 2680-2693
RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling
Endogenous satiety hormones provide an attractive target for obesity drugs. Glucagon causes weight loss by reducing food intake and increasing energy expenditure. To further understand the cellular mechanisms by which glucagon and related ligands activate the glucagon receptor (GCGR), we investigated the interaction of the GCGR with receptor activity modifying protein (RAMP)2, a member of the family of receptor activity modifying proteins. We used a combination of competition binding experiments, cell surface enzyme-linked immunosorbent assay, functional assays assessing the Gαs and Gαq pathways and β-arrestin recruitment, and small interfering RNA knockdown to examine the effect of RAMP2 on the GCGR. Ligands tested were glucagon; glucagonlike peptide-1 (GLP-1); oxyntomodulin; and analog G(X), a GLP-1/glucagon coagonist developed in-house. Confocal microscopy was used to assess whether RAMP2 affects the subcellular distribution of GCGR. Here we demonstrate that coexpression of RAMP2 and the GCGR results in reduced cell surface expression of the GCGR. This was confirmed by confocal microscopy, which demonstrated that RAMP2 colocalizes with the GCGR and causes significant GCGR cellular redistribution. Furthermore, the presence of RAMP2 influences signaling through the Gαs and Gαq pathways, as well as recruitment of β-arrestin. This work suggests that RAMP2 may modify the agonist activity and trafficking of the GCGR, with potential relevance to production of new peptide analogs with selective agonist activities.
- 6 June 2017
- Published by The Endocrine Society in Endocrinology
- Vol. 158 (8) , 2680-2693
Open AccessRAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling
Endogenous satiety hormones provide an attractive target for obesity drugs. Glucagon causes weight loss by reducing food intake and increasing energy expenditure. To further understand the cellular mechanisms by which glucagon and related ligands activate the glucagon receptor (GCGR), we investigated the interaction of the GCGR with receptor activity modifying protein (RAMP)2, a member of the family of receptor activity modifying proteins. We used a combination of competition binding experiments, cell surface enzyme-linked immunosorbent assay, functional assays assessing the Gαs and Gαq pathways and β-arrestin recruitment, and small interfering RNA knockdown to examine the effect of RAMP2 on the GCGR. Ligands tested were glucagon; glucagonlike peptide-1 (GLP-1); oxyntomodulin; and analog G(X), a GLP-1/glucagon coagonist developed in-house. Confocal microscopy was used to assess whether RAMP2 affects the subcellular distribution of GCGR. Here we demonstrate that coexpression of RAMP2 and the GCGR results in reduced cell surface expression of the GCGR. This was confirmed by confocal microscopy, which demonstrated that RAMP2 colocalizes with the GCGR and causes significant GCGR cellular redistribution. Furthermore, the presence of RAMP2 influences signaling through the Gαs and Gαq pathways, as well as recruitment of β-arrestin. This work suggests that RAMP2 may modify the agonist activity and trafficking of the GCGR, with potential relevance to production of new peptide analogs with selective agonist activities.
- Open Access
- 1 June 2017
- Published by Elsevier in Cell Reports
- Vol. 19 (11) , 2202-2209
Thyroid Hormone Receptor Beta in the Ventromedial Hypothalamus Is Essential for the Physiological Regulation of Food Intake and Body Weight
- 1 June 2017
- Published by Elsevier in Cell Reports
- Vol. 19 (11) , 2202-2209
Open AccessThyroid Hormone Receptor Beta in the Ventromedial Hypothalamus Is Essential for the Physiological Regulation of Food Intake and Body Weight
- Open Access
- 1 July 2016
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 311 (1) , E42-E55
Insights into the role of neuronal glucokinase
Glucokinase is a key component of the neuronal glucose-sensing mechanism and is expressed in brain regions that control a range of homeostatic processes. In this review, we detail recently identified roles for neuronal glucokinase in glucose homeostasis and counterregulatory responses to hypoglycemia and in regulating appetite. We describe clinical implications from these advances in our knowledge, especially for developing novel treatments for diabetes and obesity. Further research required to extend our knowledge and help our efforts to tackle the diabetes and obesity epidemics is suggested.
- 1 July 2016
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 311 (1) , E42-E55
Open AccessInsights into the role of neuronal glucokinase
Glucokinase is a key component of the neuronal glucose-sensing mechanism and is expressed in brain regions that control a range of homeostatic processes. In this review, we detail recently identified roles for neuronal glucokinase in glucose homeostasis and counterregulatory responses to hypoglycemia and in regulating appetite. We describe clinical implications from these advances in our knowledge, especially for developing novel treatments for diabetes and obesity. Further research required to extend our knowledge and help our efforts to tackle the diabetes and obesity epidemics is suggested.
- Open Access
- 11 August 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (24) , 19926-19927
Arcuate nucleus glucokinase and dietary glucose intake
- 11 August 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (24) , 19926-19927
Open AccessArcuate nucleus glucokinase and dietary glucose intake